Posted by Michael Wonder on 11 Oct 2024
FDA approves new treatment for haemophilia A or B
11 October 2024 - Product is first non-factor and once weekly treatment for haemophilia B.
Today, the US FDA approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and paediatric patients 12 years of age and older with haemophilia A without factor VIII inhibitors or haemophilia B without factor IX inhibitors (neutralising antibodies).
